Nicholas Lydon

Nicholas Lydon was the Novartis medicinal chemist who led the synthesis of the compound series that became imatinib, working in parallel with Druker's biological work to identify the phenylaminopyrimidine scaffold that selectively inhibits BCR-ABL. His chemical design of STI-571/imatinib was not initially supported by Novartis leadership, and his persistence in advancing the compound to clinical trials was essential to its development. He shared the Lasker Award with Druker for this achievement. His career represents the importance of chemistry-biology collaboration in translating target knowledge to clinical drugs.